Aims: Alzheimer's disease (AD) is one of the leading causes of death in elderly people.
| INTRODUC TI ON
Alzheimer's disease (AD) is the most common type of dementia and one of the leading causes of death in elderly people, which is characterized by neurofibrillary tangles and amyloid β-peptide (Aβ) deposits in brain. 1, 2 Based on two independent studies, the number of people newly diagnosed with AD is expected to reach 135 million around the world and 16 million in USA by 2050, respectively. 3, 4 So far, the deficiency of innate immune ability to clear Aβ deposits (rather than overproduction of them) has been widely accepted as one of the most important causes of AD pathogenesis, and current research was gradually moved from blocking the production of Aβ deposits to rebalancing the immune system of AD patients. [5] [6] [7] For example, interleukin (IL)-10, one of the best known inflammatory cytokines, was a major regulator of macrophages. 8 Recent study showed that the inhibition of the IL-10 pathway could rebalance the innate immunity and mitigate Alzheimer-like pathology. 9 Another member of interleukin family, IL-33, was found to play a potential therapeutic role for AD. A previous study reported that IL-33 could modulate the innate immune responses to reduce the accumulation of Aβ deposits and reverse the impairment of memory and synaptic plasticity in AD mouse. 10 The genome-wide association study found that a cluster of genes implicated in innate immune pathways was upregulated together with the downregulation of synaptic plasticity genes in AD patients. 11, 12 Moreover, two lymphatic systems involved in the clearance of Aβ deposits in AD were reported. In particular, glymphatic (glial+lymphatic) system was a critical contributor to the clearance of interstitial solutes (including Aβ deposits) from the brain, 13 and the function of glymphatic transport was suppressed in a mouse AD model. 14 The malfunction of meningeal lymphatic vessel (the other cleaner of Aβ deposits closely related to lymphatic system) was found to be greatly associated with AD pathogenesis. [15] [16] [17] In the meantime, some immunotherapies and drugs for Aβ clearance have attempted to control progress of AD. [18] [19] [20] For example, a monoclonal antibodybased immunotherapeutic drug was reported under development in recent year, and it selectively targeted and cleared the aggregated Aβ in brain and effectively relieved the symptom of AD. [21] [22] [23] However, only a few of drug target genes of AD implicated in immunity had been discovered up to now. Specifically, among the known target genes of therapeutic drugs for AD, only four of them (about 10.5%) belonged to the family of innate immune genes (Table   S1 , based on the information of InnateDB with over 1500 innate immune genes collected by literature review). 24 Moreover, the studies showed that the total number of the known AD drug targets had appeared to be also not complete enough, considering the wide range of pathologic features. 25 In fact, only five drugs have got FDA approval for the treatment of AD, and they target primarily on two therapeutic targets: Acetylcholinesterase and NMDA receptor. 26 Since 2003, no new target has been approved for treating AD. All the facts implied that there were still potential target genes of AD (especially the innate immune genes) remaining to be discovered.
Due to the time-consuming and extremely high cost of modern drug discovery, computational methods have emerged as one of the most effective approaches for the discovery of new targets. [27] [28] [29] [30] [31] [32] However, these computational methods focused mainly on single biologic perspective, such as pathway profile-based, 33 gene expression-based, [34] [35] [36] and similarity-based [37] [38] [39] [40] methods. Important information might be neglected by these methods, as many essential relationships (such as gene-gene, gene-disease, and disease-drug) systematically contributed to the association between the disease and their corresponding drug targets. 41 As reported, target druggability was found to be collectively defined by target's disease relevance and its roles in human protein-protein interaction network, 42 and a novel strategy integrating ontology inference and network analysis was thus proposed to predict the candidate targets of colorectal cancer (CRC). 41 In this study, the inference performance of this published method 41 was substantially enhanced by limiting the distance of reasoning and in turn reducing noise interference (prediction accuracy of ontology-based inference was reported to be highly dependent on the distance from initial nodes). 43 Then, relationships among drug, gene, SNP, disease, and haplotype were integrated by combining ontology-based inference and biological network analysis to discover potential target of AD. Finally, the enrichment analysis to the in-depth investigation of the biological functions for AD was conducted. In conclusion, this was the first discovery of drug targets for neurological disease by improving the inference performance of the newly proposed combinatorial method, and the novel candidate target genes identified in this study did provide significantly added values to the discovery of drugs for treating AD.
| MATERIAL S AND ME THODS

| Collection of AD drugs and their known targets
The drugs approved by US FDA or in clinical trial for the treatment of AD were first collected from the Therapeutic Target Database 
| Collecting the AD disease genes
To further identify the potential AD target genes from AD target genes, the levels of association between known AD disease genes and each of the candidate AD target genes were compared and ranked. The AD disease genes were searched in the AlzGene, a publicly available database collecting AD genetic variants from the publications of genetic association study about AD. To the best of our knowledge, the AlzGene is so far the only database specialized in the selection and analysis of AD risk genes, and its latest version (updated in 2011) contained 695 disease genes, 2973 polymorphisms, and 320 systematic meta-analyses performed for genotype data (including at least three case-control samples). 55 To ensure the credibility of this study, the significantly associated genes with AD (95% confidence interval of OR values should not include 1) 56 were selected for the subsequent analyses based on the results of the meta-analyses.
| Discovering potential AD target genes via association level test and aggregation rank
Based on the hypothesis that the drugs will more efficiently work on some disease genes if they show a tighter connection, 41 the levels of association between each of the candidate AD target genes and the AD disease genes were assessed to identify potential AD target genes. The human protein-protein interaction (PPI) network was thus collected for conducting such calculation.
The BioGRID (Mount Sinai Hospital, Toronto, ON, Canada) was a monthly updated comprehensive PPI network database. 57 It captured 836 212 nonredundant biological interactions from 57 058
published biomedical articles involving all major organisms and human beings by September 2016. Moreover, the different reliability of each interaction was provided in the BioGRID based on available evidences that how many independent studies consistently support the result. First, human PPI data were download from BioGRID (version 3.4.140), and the high reliability data supported by at least two independent studies were selected. Second, after removing self-interaction data, the human PPI networks which centered on each of the candidate target genes were built. Within these networks, the nodes directly linked with the candidate target genes were defined as the first-degree neighbor. Similarly, the nodes linked with the first-degree neighbors (except the candidate AD target genes) were defined as the second-degree neighbors, and the nodes linked with the second-degree neighbors (except first-degree neighbors) were defined as the third-degree neighbors, etc. Thirdly, the previous studies showed that the disease genes were mainly enriched in the first three degree neighbors of the drug target genes. 58, 59 Thus, the AD disease genes to the first-, second-, third-degree neighbors of the PPI networks were mapped, and their percentages in each neighbor to assess the levels of association between each of the candidate AD target genes and AD disease genes were calculated. Specifically, for a given AD candidate gene, there were N genes in its first-degree neighbor, and of which n genes belong to AD disease genes. Then, the closer that this ratio (n/N) was to 1, the more significant association was built between this given AD candidate gene and AD disease genes.
Thus, this given candidate gene more likely becomes a potential drug target. Similarly, the ratio in other degree neighbors was calculated by this approach. Finally, based on the ratios in the three degree neighbors, the candidate AD target genes were ranked in three lists.
To identify the potential AD drug targets, robust rank aggregation (RRA) method was used to integrate the three lists of rank order. RRA was a computationally efficient and statistically stable order algorithm, and it assigned the P-value to measure how well a candidate gene was positioned in the ranked lists than expected by chance. 60 The R package of RRA (RobustRankAggreg) was available at the Comprehensive R Archive Network (https://www.icesi. edu.
co/CRAN/web/packages/RobustRankAggreg/).
| Enrichment analysis of the potential AD drug target genes
AD was reported to be closely related to immune system, 5,61 but very little of immune-relevant AD drug target genes had been discovered comparing with other target genes. Therefore, it was possible that there were more potential immune-relevant genes than others among the undiscovered AD drug target genes. were fully downloadable, and the enrichment analyses of the potential AD drug target genes based on data from these eight databases were thus conducted using the R package clusterProfiler 71 to validate the presumption of this study.
| RE SULTS AND D ISCUSS I ON
| Collecting AD drugs and limiting search criteria using their known targets
First, by selecting AD drugs from TTD database 72 and removing the drugs not belonging to PharmGKB database, 73 five approved and one phase III clinical trial drugs were obtained. Second, 23 known targets of these drugs were collected from TTD and DrugBank. 48, 49 Third, to limit the distance of reasoning, the number of the known AD target genes was counted in each degree of OWL network. As demonstrated in Table 1 , for the selected drugs, their known target genes were mainly concentrated in a specific degree. These results implied that for a given drug, its target genes were mainly distributed in a specific scope of OWL network. In this study, to reduce the effect of noise, the reasoning distance of each drug was thus limited to the degree where most of its known target genes can be found.
| Discovering the candidate AD target genes using OWL ontology method
An OWL ontology of AD drug, gene, SNP, disease, and haplotype was built based on their relationship in PharmGKB, and the reason- The nodes directly linked with a certain drug according to the relationships of PharmGKB are defined as degree 1. The nodes linked with this drug through degree 1 are defined as degree 2. Degree 3, degree 4, and degree 5 are defined by similar way. NaN means that the known drug target gene is not in this degree. "Mode value of degrees" means that most of the known drug target genes are found in this degree.
in Figures 1 and S1 . After eliminating duplicate data, 623 candidate AD target genes directly or indirectly connected with one of the AD drugs were discovered, and 109 of them had been reported to be closely related to AD.
| Identifying the potential AD target genes by AD disease genes and RRA method
First, 41 AD disease genes confirmed by meta-analysis (including at least three case-control experiments) were collected from AlzGene database (Table S2) . Second, 623 human PPI networks of candidate AD target genes were built by BioGRID data. Third, the 41 AD disease genes were mapped to the first-, second-, and third-degree neighbors of the 623 PPI networks, and the percentages of AD disease genes in each degree neighbor were calculated to rank these candidate target genes at 3 different levels. Finally, these three levels of rank were integrated using RRA method. As shown in Table 2, 18 potential AD target genes with significant P-values (<0.05) were identified, and of which 13 genes were reported to be closely associated with AD by previous studies.
Taking RELN gene (coding reelin, an extracellular matrix glycoprotein) as an example, it participated in the regulation of neuronal migration, position, growth, and synaptic plasticity linking memory/ learning formation, 74 and it could prevent synaptic dysfunction induced by accumulation of Aβ deposits in AD. 75 Some studies reported a significant association between RELN and AD among different populations. [76] [77] [78] Another example could be DNMBP, which was a scaffold protein to bring dynamin and actin regulatory proteins together 79 and participated in synaptic vesicle trafficking. [80] [81] [82] This process could be disturbed by accumulation of Aβ deposits in AD. 83 Previous studies have reported significant association between DNMBP and AD in Japanese population. 84 The following studies also found a significant association between DNMBP and AD in Belgian and Chinese populations. 85, 86 The distribution of 13 reported genes in the 18 identified potential AD target genes were calculated. The 18 potential target genes identified in this study were first arranged in the descending order of P-values of robust rank aggregation (RRA) analysis. Second, the cumulative number N was defined as the first N potential target genes, and the percentage of reported genes in each cumulative number F I G U R E 1 Process of discovering the candidate AD target genes from each final selected AD drug. Each part of this figure shows the process of discovery from one of the drugs, respectively. The process of discovery from memantine is shown in Figure S1 because it is relatively complex. Different colors of the nodes mean different data types. In particular, green represents gene, yellow represents drug, red represents disease, purple represents haplotype, and gray represents SNP. The nodes with red and blue circles represent known targets and linkage nodes, respectively. The annulus areas constituted of these nodes represent different discovery degrees. Only the linkage nodes and the discovered candidate target genes are retained in this figure. The duplicate data have been eliminated. This figure can be viewed more clearly by enlarging in the electronic version was calculated. As shown in Figure 2 , the slope of the fitted curve is continually decreasing. This phenomenon reflected a good reliability of the applied prediction method because it was consistent between the significance of potential AD target genes and the possibility of it being an AD associated gene. Specifically, nearly half of the genes reported to be closely associated with AD were gathered in the first 30% identified potential target genes. Then, another phenomenon was observed by comparing candidate and potential AD target genes. Percentage of reported genes were significantly higher in potential AD target genes (about 72.2%) than it in candidate AD target genes (about 17.5%), which further reflect the reliability of the prediction.
| Enrichment analysis of the potential target genes based on pathway-related databases
To explore the function of those 18 identified potential AD target genes, the KEGG enrichment analysis was conducted. As shown in Table 3 , two KEGG pathways were enriched in this analysis by setting the P-value cutoff as 0.01, and both belonged to the human immune disease. If the P-value cutoff was further set as 0.05, six KEGG pathways could be enriched, and they all belonged to immune disease or immune system. The remaining KEGG pathway (Type I diabetes mellitus) was also an autoimmune disease. 87, 88 Altogether, these pathways contained four immune genes: C1QB, HLA-B, IL-10, and CD86. Among these genes, C1QB coded the B chain of complement Extensive enrichment analyses on these potential drug target genes based on eight databased providing the pathway information (MetaCyc, NetPath, PathWhiz, PID, and WikiPathways) and were further conducted to reveal their functions. Apart from PID, the data of the remaining seven databases were fully downloadable, and the enrichment analyses of the potential AD target genes based on the data from the seven databases were thus conducted using R package clusterProfiler to validate the presumption of this study.
As a result, no term was enriched based on the data of PANTHER, PathWhiz, MetaCyc, and NetPath, and the enriched terms based on GO, Reactome, and WikiPathways databases are provided in Tables   4, S3 
| CON CLUS IONS
A total of 18 potential AD target genes were identified by the combinatorial method of ontology-based inference and biological network analysis. Further, the results of enrichment analysis showed that these 18 potential AD target genes were significantly enriched in the immune-related pathways, and of which C1QB, HLA-B, IL-10, and CD86 were involved in the process of antigen presenting from MHC to T cell. These results implied that the pathogenic mechanism of AD may be relevant to the abnormal process of antigen presenting and may be an effective point of further drug development. In summary, our findings showed the importance of immune-related drug target genes to the therapy of AD and would benefit to the AD research in the future. 
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TA B L E 4 GO enrichment results of the potential AD drug target genes identified in this study The adjusted P-values are obtained through multiple hypothesis testing to correct the nominal P-values.
